Lower dose chemo after stem cell transplant for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a lower dose of the chemotherapy drug cyclophosphamide given after a stem cell transplant is safe and effective for people with blood cancers. The goal is to reduce side effects while still helping prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your daily activity level is good (you can do light housework or desk work).
- You do not have an active, uncontrolled infection.
- Your heart is working well (ejection fraction 45% or higher, no serious rhythm problems).
- Your lungs are functioning well (breathing tests are at least 50% of normal).
- Your kidneys and liver are working well (creatinine clearance over 60 mL/min, and liver enzymes within safe limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This trial tests a lower dose of the drug cyclophosphamide after a stem cell transplant from a half-matched donor. It aims to see if the lower dose works just as well to prevent graft-versus-host disease, with fewer side effects.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
This trial tests whether a lower dose of a common drug (cyclophosphamide) after transplant can prevent graft-versus-host disease (a complication where donor cells attack your body) just as well as the standard dose. It also uses another medicine (anti-thymocyte globulin) after the transplant to help protect you.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.